In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Blueprint Medicines (BPMC – Research Report), with a price target of $100.00. The company's shares closed last Tuesday at $56.29. According to TipRanks.com, Fein is ranked 0 out of 5 stars with an average return of -16.3% and a 32.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Global Blood Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $81.00 average price target, representing a 62.0% upside.
https://www.tipranks.com/news/blurbs/blueprint-medicines-bpmc-gets-a-buy-rating-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Sep 2022 to Oct 2022 Click Here for more Blueprint Medicines Charts.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Oct 2021 to Oct 2022 Click Here for more Blueprint Medicines Charts.